SEDDS Formulation Enhances Tocotrienol Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tocotrienols have low or erratic oral bioavailability due to their low affinity for transport proteins and rapid metabolism, which limits their effectiveness as antioxidants and nutritional supplements.
Innovation Solution
A self-emulsifying drug delivery system (SEDDS) formulation comprising Vitamin E polyethylene glycol 1000 succinate (TPGS), an oil carrier, and a phospholipid, which enhances the oral bioavailability of lipophilic compounds like tocotrienols by inhibiting P-glycoprotein and CYP3A4 metabolism, promoting spontaneous micellization and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tocotrienols are administered orally, then they can be absorbed and distributed throughout the body, but their oral bioavailability is low or erratic due to low affinity for transport proteins
Solution Approach 1:
The patent employs alpha-tocopherol as an intermediary substance to facilitate the transport of tocotrienols across the intestinal barrier. Since tocotrienols have low affinity for alpha-tocopherol transport proteins (α-TTP), co-administration of alpha-tocopherol allows tocotrienols to 'hitchhike' on the transport mechanism, significantly improving their oral bioavailability and consistency of absorption.
2Reliability
If conventional emulsions are used to improve oral absorption of tocotrienols, then bioavailability increases, but the formulation becomes bulky with shorter shelf life and reduced palatability
Solution Approach 1:
The patent utilizes the self-emulsifying property of medium-chain triglyceride (MCT) oil to automatically form micelles in the gastrointestinal tract without requiring external emulsification equipment or complex formulation processes. This self-service approach improves oral bioavailability of tocotrienols while avoiding the bulkiness and stability issues associated with conventional emulsions, and maintains better palatability.
3Quantity of substance
If tocotrienols are given at very high concentration, then they can achieve therapeutic effects, but they potentiate P-glycoprotein transfer activity in intestinal cells reducing absorption
Solution Approach 1:
The patent uses alpha-tocopherol as a mediator to enhance tocotrienol absorption through α-TTP transport proteins. This intermediary mechanism allows tocotrienols to bypass the P-glycoprotein efflux system that limits high-concentration absorption, enabling therapeutic doses to be achieved while maintaining reliable and consistent oral bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SEDDS formulation achieves a 2 to 3-fold increase in oral bioavailability of tocotrienols compared to conventional formulations, with enhanced stability and absorption, exceeding the bioavailability improvements of existing SEDDS technologies.
Implementation Method 1
Vitamin E TPGS has been demonstrated to improve the oral bioavailability of lipophilic tocotrienols by its ability to inhibit the efflux mechanism of P-glycoprotein in the intestinal cells
Implementation Method 2
Vitamin E TPGS has been demonstrated to improve the oral bioavailability of lipophilic tocotrienols by its ability to inhibit the metabolism by CYP3A4 enzyme
Implementation Method 3
promoting spontaneous micellization and stability
Data Source
AI summary
The present invention relates to a self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound comprising a lipophilic compound, a Vitamin E polyethylene glycol 1000 succinate (TPGS), an oil carrier and a phospholipid. The present invention also relates to the use of the self-emulsifying drug delivery system in the manufacture of a dietary supplement with improved oral bioavailability of lipophilic compound.